Compare Amgen, Inc. (AMGN) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Tripadvisor Inc Common Stock trades at $13.89 (market cap $1.63B). The key difference: Amgen, Inc. is far larger — about 120.3× Tripadvisor Inc Common Stock's market cap, and Amgen, Inc. pays a 2.77% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| AMGN | TRIP | |
|---|---|---|
Market Cap | $196.12B | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $19.14 |
52-Week Low | $271.18 | $9.24 |
Enterprise Value | $241.41B | $1.75B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TRIP trades at $13.98, up 4.88% today, near the consensus price target of $13.87. The stock shows a bullish technical signal with support at $13 and resistance at $14. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company's $700 million sale of TheFork to American Express in June 2026 provides a cash infusion but highlights strategic refocusing amid competitive pressures.
The outlook is cautious; while the sale simplifies the business and boosts liquidity, core revenue growth remains modest and net margins are thin at 0.99%. Analyst sentiment is neutral with 60.72% hold ratings. Key risks include execution on the narrowed strategy and travel industry volatility. The stock appears fairly valued with a P/E of 127.09 reflecting low earnings, but the P/S of 0.93 suggests potential if top-line expansion accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
